



Canadian
Cancer Clinical
Trials Network

Réseau canadien
d'essais cliniques
sur le cancer

Canadian Cancer Clinical Trials Network

3CTN Y7 Performance Report

April 1, 2020 – March 31, 2021


Table of Contents

Section A: Patient Access and Recruitment to the 3CTN Portfolio Trials.....	2
Patient Recruitment at All Network Sites.....	2
Portfolio Trials and Accruals by Region/Site.....	3
Patients recruited to 3CTN Portfolio trials, FY2020/21 (Y7) – BC, Alberta, and Manitoba	3
Number of active recruiting 3CTN Portfolio trials – BC, Alberta, and Manitoba	4
Patients recruited to 3CTN Portfolio trials, FY2020/21 (Y7) – Ontario	5
Number of active recruiting 3CTN Portfolio trials – Ontario	6
Patients recruited to 3CTN Portfolio trials, FY2020/21 (Y7) – Atlantic Region and Quebec	7
Number of active recruiting 3CTN Portfolio Trials – Atlantic Region and Quebec	8
Patients recruited to 3CTN Portfolio trials, FY2020/21 (Y7) – Pediatric Cancer Centres	9
Number of active recruiting 3CTN Portfolio Trials – Pediatric Cancer Centres	10
Section B: 3CTN Portfolio Metrics	11
Active Recruiting Portfolio Trials by Disease Site and Phase.....	11
Overview of Portfolio Applications – Process Efficiency.....	12
Trials Added to the 3CTN Portfolio in Y7Q4 (Jan 1-Mar 31, 2021)	13

Section A: Patient Access and Recruitment to the 3CTN Portfolio Trials

Patient Recruitment at All Network Sites

Objective: To improve patient access to academic clinical trials and improve patient recruitment by greater than 75% within four years.



* 1 centre in the Atlantic region did not report in Y7

**Pediatric centres don't have a recruitment target; therefore, the graph shows Pediatric progress to pre-3CTN baseline recruitment.

Notes:

- 1776 patients were recruited to 3CTN Portfolio trials in Quarter 4, bringing the year's total accrual to 5403 patients and exceeding the overall Network target of 4468 patients (65% above pre-3CTN baseline).
- Overall, ~36% (15 out of 42) of adult sites exceeded their individual Y7 recruitment targets
- 40% (6 out of 15) of pediatric sites exceeded their individual Pre-3CTN baseline recruitment

Portfolio Trials and Accruals by Region/Site

Patients recruited to 3CTN Portfolio trials, FY2020/21 (Y7) – BC, Alberta, and Manitoba

Network Site	Pre-3CTN Baseline	Y2 Total	Y3 Total	Y4 Total	Y5 Total	Y6 Total	Year 7 (2020-21)						
							Q1	Q2	Q3	Q4	Total	% of Baseline	% to Target
CancerCare Manitoba	99	72	102	90	98	51	3	9	15	17	44	44%	27%
Western Manitoba Cancer Centre	1	0	0	0	1	1	0	0	0	0	0	0%	0%
Manitoba Total	100	72	102	90	99	51	3	9	15	17	44	44%	27%
BC Cancer – Vancouver	106	117	152	127	107	110	21	41	32	60	154	145%	88%
BC Cancer – Abbotsford	16	28	14	22	22	1	1	0	0	0	1	6%	4%
BC Cancer – Prince George	1	6	4	8	9	10	3	0	5	6	14	1400%	700%
BC Cancer – Kelowna	38	40	30	28	38	33	12	13	4	7	36	95%	57%
BC Cancer – Victoria	26	44	69	64	69	78	4	19	6	11	40	154%	93%
British Columbia Total	187	235	269	249	245	232	41	73	47	84	245	131%	79%
Cross Cancer Institute	102	112	137	99	103	310	36	74	16	76	202	198%	120%
Tom Baker Cancer Centre	76	140	125	154	139	341	56	82	9	101	248	326%	198%
Alberta Total	178	252	262	253	242	651	92	156	25	177	450	253%	153%
Western Region Total	465	559	633	592	586	934	136	238	87	278	739	159%	96%

Number of active recruiting 3CTN Portfolio trials – BC, Alberta, and Manitoba

Network Site	Pre-3CTN Baseline	Y5 (2018-19)				Y6 (2019-20)				Y7 (2020-21)			
		Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
CancerCare Manitoba	37	28	27	29	23	22	19	16	22	13	20	18	17
Western Manitoba Cancer Centre	0	0	0	1	1	1	1	1	1	1	1	1	1
BC Cancer – Vancouver	50	25	25	27	27	26	25	23	27	16	17	19	28
BC Cancer – Abbotsford	6	4	4	4	4	5	5	0	0	1	1	0	0
BC Cancer – Prince George	2	3	3	3	3	2	2	3	3	4	5	4	6
BC Cancer – Kelowna	23	9	10	6	6	5	5	5	7	4	5	5	5
BC Cancer – Victoria	12	5	6	5	5	8	7	6	6	7	9	7	10
Cross Cancer Institute	29	29	28	30	29	27	26	27	21	14	25	22	22
Tom Baker Cancer Centre	20	29	32	32	30	30	34	33	33	28	28	23	25

Note: COVID-19 caused a majority of recruitment to open trials and new trial activations to be put on hold during Y7Q1; a majority of sites were able to resume trial operations in Y7Q2.

Patients recruited to 3CTN Portfolio trials, FY2020/21 (Y7) – Ontario

Network Site	Pre-3CTN Baseline	Y2 Total	Y3 Total	Y4 Total	Y5 Total	Y6 Total	Year 7 (2020-21)						
							Q1	Q2	Q3	Q4	Total	% of Baseline	% to Target
London Health Sciences Centre	186	172	187	169	248	942	43	161	238	251	693	373%	226%
Grand River Regional Cancer Centre	20	13	43	32	34	19	9	5	7	3	24	120%	73%
Windsor Regional Cancer Centre	14	17	63	32	16	3	0	0	1	1	2	14%	9%
Juravinski Cancer Centre	181	231	247	454	345	217	16	32	35	59	142	78%	47%
Cambridge Memorial Hospital	11	2	5	4	5	8	3	4	2	0	9	82%	50%
St. Joseph's Healthcare Hamilton	21	30	54	74	40	20	6	8	16	24	54	257%	154%
Walker Family Cancer Centre	17	22	13	23	37	40	1	3	2	1	7	41%	25%
Sunnybrook Health Sciences Centre	141	229	398	363	651	638	33	74	144	136	387	274%	166%
Humber River Hospital	1	2	1	9	7	3	1	1	1	1	4	400%	200%
Michael Garron Hospital	2	2	1	7	2	0	0	0	0	0	0	0%	0%
Princess Margaret Cancer Centre	396	384	533	473	720	543	14	62	83	108	267	67%	41%
Markham Stouffville Hospital	1	0	28	9	2	6	0	3	0	0	3	300%	150%
Mount Sinai Hospital	21	12	40	7	12	7	0	0	0	67	67	319%	191%
Northeast Cancer Centre	24	17	12	9	18	17	0	0	1	6	7	29%	18%
North York General Hospital	1	4	8	11	9	7	0	1	1	5	7	700%	350%
Royal Victoria Regional Health Centre	8	18	58	23	9	25	4	1	3	5	13	163%	100%
St. Michael's Hospital	19	0	27	2	1	3	0	0	0	0	0	0%	0%
Southlake Regional Health Centre	10	15	75	26	68	32	1	5	3	0	9	90%	53%
Thunder Bay Regional Health Sciences Centre	26	3	46	16	25	4	0	0	1	1	2	8%	5%
Trillium Health Partners - Credit Valley Hospital	27	5	51	10	12	10	0	0	0	2	2	7%	4%
William Osler Health System	1	0	29	13	0	16	0	0	0	2	2	200%	100%
The Ottawa Hospital Cancer Centre	132	238	396	500	850	804	75	130	172	106	483	366%	222%
Cancer Centre of Southeastern Ontario at Kingston General Hospital	41	58	122	84	72	89	17	14	17	11	59	144%	87%
R.S. McLaughlin Durham Regional Cancer Centre	22	26	70	18	15	36	0	2	1	0	3	14%	8%
Central Region Total	1323	1500	2507	2368	3198	3489	223	506	728	789	2246	170%	103%

Number of active recruiting 3CTN Portfolio trials – Ontario

Network Site	Pre-3CTN Baseline	Y5 (2018-19)				Y6 (2019-20)				Y7 (2020-21)			
		Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
London Health Sciences Centre	79	45	46	46	40	47	52	54	57	45	47	44	41
Grand River Regional Cancer Centre	11	8	8	8	8	6	7	8	8	8	8	8	8
Windsor Regional Cancer Centre	4	4	4	5	5	4	4	4	3	4	2	2	2
Juravinski Cancer Centre	51	29	27	30	32	22	26	24	34	13	31	34	35
Cambridge Memorial Hospital	5	2	2	3	2	2	2	2	2	2	2	2	2
St. Joseph's Healthcare Hamilton	2	3	2	2	3	1	1	1	1	1	1	2	2
Walker Family Cancer Centre	10	8	7	8	7	6	6	8	7	8	7	7	7
Sunnybrook Health Sciences Centre	10	32	34	34	35	34	36	36	35	47	35	34	33
Humber River Hospital	0	3	3	2	2	2	2	3	2	3	2	1	1
Michael Garron Hospital	3	2	2	2	2	1	1	1	1	1	1	1	1
Princess Margaret Cancer Centre	91	71	74	81	86	78	88	89	80	80	81	82	65
Markham Stouffville Hospital	0	0	0	1	1	1	0	1	1	1	1	1	1
Mount Sinai Hospital	6	4	4	4	4	4	5	6	3	3	2	2	3
Northeast Cancer Centre	10	6	7	7	8	7	7	7	7	8	7	7	8
North York General Hospital	0	3	4	3	3	3	5	4	1	2	3	4	4
Royal Victoria Regional Health Centre	5	8	6	6	6	6	6	9	10	10	9	10	10
St. Michael's Hospital	4	1	1	1	2	2	2	3	2	2	2	1	1
Southlake Regional Health Centre	3	9	10	10	10	9	8	8	7	6	6	6	6
Thunder Bay Regional Health Sciences Centre	8	5	5	5	5	5	5	4	3	0	0	3	3
Trillium Health Partners - Credit Valley Hospital	9	3	3	3	4	4	4	3	6	0	0	1	4
William Osler Health System	0	1	1	2	2	1	2	2	2	1	1	1	3
The Ottawa Hospital Cancer Centre	56	38	37	41	51	41	36	34	15	10	27	29	35
Cancer Centre of Southeastern Ontario at Kingston General Hospital	18	26	25	25	26	21	33	33	22	21	21	21	20
R.S. McLaughlin Durham Regional Cancer Centre	13	3	4	3	3	3	3	2	2	0	2	1	1

Note: COVID-19 caused a majority of recruitment to open trials and new trial activations to be put on hold during Y7Q1; a majority of sites were able to resume trial operations in Y7Q2.

Patients recruited to 3CTN Portfolio trials, FY2020/21 (Y7) – Atlantic Region and Quebec

Network Site	Pre-3CTN Baseline	Y2 Total	Y3 Total	Y4 Total	Y5 Total	Y6 Total	Year 7 (2020-21)						
							Q1	Q2	Q3	Q4	Total	% of Baseline	% to Target
Nova Scotia Health Authority	39	40	52	45	42	20	DNR	DNR	DNR	DNR	-	-	-
Eastern Regional Health Authority	15	4	12	8	15	16	0	0	0	5	5	33%	20%
Atlantic Total	54	97	112	88	57	36	0	0	0	5	5	9%	6%
CIUSSS du Centre-Ouest-de-l'Île-de-Montréal (CIUSSS CODIM)	87	76	161	149	71	155	9	21	22	38	90	103%	63%
CISSS de l'Outaouais	3	0	4	32	1	5	0	0	1	1	2	67%	40%
CHU de Québec – Université Laval, adults	180	25	144	236	99	309	14	64	146	148	372	207%	125%
CIUSSS de l'Estrie – Centre hospitalier universitaire de Sherbrooke, adults (CIUSSS-Estrie-CHUS)	46	16	70	55	18	61	0	4	3	4	11	24%	14%
Centre Hospitalier de l'Université de Montréal (CHUM)	153	59	123	149	112	66	4	13	36	20	73	48%	29%
CIUSSS du Nord-de-l'Île-de-Montréal (CIUSSS NDIM)	3	0	4	16	8	539	0	517	671	415	1603	53433%	32060%
CIUSSS de l'Est-de-l'Île-de-Montréal (CIUSSS EDIM)	60	12	51	49	23	15	0	2	3	1	6	10%	6%
Quebec Total	532	192	588	709	332	1150	27	621	882	627	2157	405%	246%
Eastern Region Total	586	289	700	797	389	1186	27	621	882	632	2162	369%	224%

DNR= Did Not Report

Number of active recruiting 3CTN Portfolio Trials – Atlantic Region and Quebec

Network Site	Pre-3CTN Baseline	Y5 (2018-19)				Y6 (2019-20)				Y7 (2020-21)			
		Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
Nova Scotia Health Authority	14	12	16	17	17	19	14	17	16	14	14	14	14
Eastern Regional Health Authority	6	4	6	5	6	8	9	10	9	0	6	7	7
CIUSSS du Centre-Ouest-de-l'Île-de-Montréal (CIUSSS CODIM)	27	N/A	N/A	N/A	N/A	18	15	24	17	17	18	17	25
CISSS de l'Outaouais	1	1	1	1	2	2	2	2	2	2	1	1	2
CHU de Québec – Université Laval, adults	39	19	20	26	26	26	26	25	30	27	30	30	23
CIUSSS de l'Estrie – Centre hospitalier universitaire de Sherbrooke, adults (CIUSSS-Estrie-CHUS)	10	13	11	13	16	14	15	17	17	16	13	14	13
Centre Hospitalier de l'Université de Montréal (CHUM)	28	32	34	37	37	33	30	33	30	29	27	27	27
CIUSSS du Nord-de-l'Île-de-Montréal (CIUSSS NDIM)	4	2	2	2	2	2	3	3	2	0	3	3	3
CIUSSS de l'Est-de-l'Île-de-Montréal (CIUSSS EDIM)	6	12	13	11	10	10	8	11	10	9	9	10	9

Note: COVID-19 caused a majority of recruitment to open trials and new trial activations to be put on hold during Y7Q1; a majority of sites were able to resume trial operations in Y7Q2.

Patients recruited to 3CTN Portfolio trials, FY2020/21 (Y7) – Pediatric Cancer Centres

Network Site	Pre-3CTN Baseline	Y2 Total	Y3 Total	Y4 Total	Y5 Total	Y6 Total	Year 7 (2020-21)					
							Q1	Q2	Q3	Q4	Total	% of Baseline
Alberta Children's Hospital	21	21	10	14	-	-	5	5	4	5	19	90%
BC Children's Hospital	34	46	41	31	-	-	2	10	10	8	30	88%
CancerCare Manitoba - Pediatrics	18	20	14	17	4	7	4	5	2	1	12	67%
Centre hospitalier universitaire de Sainte-Justine	42	26	44	40	38	38	12	11	12	16	51	121%
Children's Hospital - London Health Sciences Centre	12	15	26	9	-	-	1	2	2	0	5	42%
Children's Hospital of Eastern Ontario	20	18	35	31	-	-	2	1	7	4	14	70%
CHU de Québec-Université Laval / Centre Mère-Enfant Soleil	17	14	7	17	22	21	8	5	7	9	29	171%
IWK Health Centre	20	20	16	40	-	-	0	3	1	2	6	30%
Janeway Children's Health and Rehabilitation Centre	4	3	4	4	0	0	3	0	2	0	5	125%
McMaster Children's Hospital - Hamilton Health Sciences Centre	14	20	19	28	-	-	0	7	5	4	16	114%
Montreal Children's Hospital	24	23	14	20	8	10	2	4	4	6	16	67%
Saskatchewan Pediatric Hematology Oncology Program	6	6	5	4	-	-	2	0	2	3	7	117%
Stollery Children's Hospital	11	10	26	33	-	-	6	4	6	4	20	182%
The Hospital for Sick Children	91	109	89	69	-	-	1	3	7	15	26	29%
Pediatric Total	334	351	350	357	72	76	48	60	71	77	256	77%


Number of active recruiting 3CTN Portfolio Trials – Pediatric Cancer Centres

Network Site	Pre-3CTN Baseline	Y5 (2018-19)				Y6 (2019-20)				Y7 (2020-21)			
		Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
Alberta Children's Hospital	9	-	-	-	-	-	-	-	-	22	23	24	15
BC Children's Hospital	15	-	-	-	-	-	-	-	-	13	15	15	17
CancerCare Manitoba - Pediatrics	19	17	17	15	13	10	9	8	9	9	11	11	13
Centre hospitalier universitaire de Sainte-Justine	9	30	22	22	24	17	18	18	17	17	18	19	22
Children's Hospital - London Health Sciences Centre	5	-	-	-	-	-	-	-	-	14	14	15	18
Children's Hospital of Eastern Ontario	8	-	-	-	-	-	-	-	-	8	11	12	17
CHU de Québec-Université Laval / Centre Mère-Enfant Soleil	11	13	16	17	15	17	15	13	11	15	15	15	20
IWK Health Centre	9	-	-	-	-	-	-	-	-	19	20	22	23
Janeway Children's Health and Rehabilitation Centre	5	11	9	9	9	5	9	6	6	7	8	8	10
McMaster Children's Hospital - Hamilton Health Sciences Centre	8	-	-	-	-	-	-	-	-	12	13	14	17
Montreal Children's Hospital	5	25	25	20	21	12	16	16	13	16	17	15	22
Saskatchewan Pediatric Hematology Oncology Program	7	-	-	-	-	-	-	-	-	8	8	8	8
Stollery Children's Hospital	3	-	-	-	-	-	-	-	-	9	11	13	13
The Hospital for Sick Children	13	-	-	-	-	-	-	-	-	16	17	17	23

Section B: 3CTN Portfolio Metrics

Active Recruiting Portfolio Trials by Disease Site and Phase

Objective: To monitor and optimize the Portfolio in order to create opportunities for new trials and demonstrate 3CTN's impact.



Overview of Portfolio Applications – Process Efficiency

Objective: To improve Portfolio application processing time.

Portfolio Approval Process Timeline¹

Calendar Year	Number of Applications Received	# Applications Completed	Average Application Processing Time (days)	Median Application Processing Time (days)
2015	90	85	16	7
2016	70	71	31	6
2017	45	47	22	6
2018	46	44	18	5
2019	45	45	42	3
2020	41	41	27	0
2021	38	37	22	1

Facilitated Peer Review (FPR) Process

Calendar Year	Number of FPR Requests	# FPR Completed ²	Average FPR Time (days) ³	Median FPR Time (days) ³
2015	6	3	28	28
2016	11	12	76	62
2017	4	5	106	77
2018	10	7	86	74
2019	16	17	98	83
2020	7	6	137	134
2021	4	5	127	113

¹ From application received to approve/decline the application for period, Jan 13, 2015 to June 16, 2021.

² Counts are based on the completed applications in that calendar year, e.g. for an application submitted for review in 2019 but completed the review process in 2020, the FPR time will be used for the 2020 calculation.

³ FPR process time is from the start date of peer review (i.e. site agreed to pursue peer review) to the date the last reviewer package is submitted to 3CTN (completed trials only).

Additional link to interactive Portfolio Application report: [Portfolio Applications Report](#)

3CTN Performance Report

Recruitment database lock & Portfolio snapshot date: June 16, 2021

Trials Added to the 3CTN Portfolio in Y7Q4 (Jan 1-Mar 31, 2021)

Trial short title	Trial phase	Disease site	Complexity rating	Canadian trial status	Trial link
(BCC) BCC015	Phase II	Neuroblastoma	High	Open to recruitment	NCT04301843
(BCC) NMTRC012	Phase II	Neuroblastoma	High	Open to recruitment	NCT02559778
(BCC) NMTRC014	Phase II	Neuroblastoma	High	Open to recruitment	NCT02679144
(CCTG) CO.29 / DYNAMIC III	Phase II/III	Gastrointestinal	Standard	Open to recruitment	ACTRN12617001566325
(CCTG) PR.21	Phase II	Genito-Urinary	Standard	Open to recruitment	NCT04663997
(CCTG) SR.7	Phase III	Sarcoma	Standard	Open to recruitment	NCT04031677
(Chicago) IRB19-1718/Immunotherapy De-Escalation Trial	Phase I	Other	High	Project in Setup	NCT04295863
(COG) AALL1821	Phase II	Hematology	High	Open to recruitment	NCT04546399
(COG) AAML1831	Phase III	Hematology	High	Open to recruitment	NCT04293562
(COG) ACNS1931	Phase III	Brain/CNS	High	Open to recruitment	NCT04576117
(COG) ADVL1823	Phase II	Other	High	Open to recruitment	NCT03834961
(COG) AREN1921	Phase II	Genito-Urinary	High	Open to recruitment	NCT04322318
(NACHO) LCH-IV	Phase II/III	Other	High	Open to recruitment	NCT02205762
(OHRI) AIRPORT-MPN-001	Phase II	Hematology	Low	Open to recruitment	NCT04243122
(OHRI) REaCT-HOLD BMA	Phase IV	Other	Low	Open to recruitment	NCT04549207
(SJHH) PSPM	Phase II	Lung	Low	Open to recruitment	NCT04160143
(UHN) NeoPancONE / OZM-101	Phase II	Gastrointestinal	Low	Open to recruitment	NCT04472910
NRG-GY019	Phase III	Gynecological	Standard	Open to recruitment	NCT04095364
RTOG 3507 / KEYSTROKE	Phase II	Head and neck	Standard	Open to recruitment	NCT03546582

Additional link to interactive Portfolio trial listing: [3CTN's Portfolio Trial Listing](#)